CSL Ltd Annual Report 2021

Plant and Equipment US$m Right-of-use assets US$m Capital work in progress US$m Total US$m 2021 2020 2021 2020 2021 2020 2021 2020 3,603.4 3,302.9 1,587.6 1,347.2 3,627.8 2,852.5 10,368.6 8,784.3 (1,936.3) (1,714.6) (485.9) (407.8) – – (2,832.6) (2,478.9) 1,667.1 1,588.3 1,101.7 939.4 3,627.8 2,852.5 7,536.0 6,305.4 1,588.3 1,468.6 939.4 925.8 2,852.5 2,221.0 6,305.4 5,410.1 266.5 297.0 – – (502.6) (474.4) 0.9 – 49.0 63.2 238.8 85.3 1,318.5 1,124.6 1,610.0 1,273.1 (4.1) (18.4) – – (8.1) (8.2) (12.3) (29.4) – – – – – (0.5) – (5.1) (272.4) (229.3) (77.1) (71.7) – – (399.4) (347.3) – – – – (74.4) – (74.4) – 39.8 7.2 0.6 – 41.9 (10.0) 105.8 4.0 1,667.1 1,588.3 1,101.7 939.4 3,627.8 2,852.5 7,536.0 6,305.4 Note 9: Deferred Government Grants 2021 US$m 2020 US$m Current deferred income 49.7 3.2 Non-current deferred income 37.2 40.1 Total deferred government grants 86.9 43.3 Government grants are recognised at their fair value where there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions. During the year the Group received government grants for various activities including the manufacture and development of vaccines as well as the development of facilities. Government grants relating to an expense item are deferred and recognised in the statement of comprehensive income against the related costs over the period necessary to match themwith the expenses that they are intended to compensate. Government grants received for which there are no future related costs are recognised in the statement of comprehensive income immediately. Government grants relating to the purchase or construction of property, plant and equipment are included in current and non-current liabilities as deferred income and are released to the statement of comprehensive income on a straight-line basis over the expected useful lives of the related assets. CSL Limited Annual Report 2020/21 125